$-2.10
(Market cap
$1,445 Mln
Revenue (TTM)
$276 Mln
P/E Ratio
--
P/B Ratio
96.2
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-1.2 %
-
ROCE
-- %
-
Industry P/E
37.91
-
EV/EBITDA
147.6
-
Debt to Equity
19.2
-
Book Value
$--
-
EPS
$-1
-
Face value
--
-
Shares outstanding
37,487,850
10 Years Aggregate
CFO
$-27.05 Mln
EBITDA
$-33.68 Mln
Net Profit
$-104.98 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Harrow Health (HROW)
| -29.6 | -15.3 | -4.0 | -11.3 | 32.4 | 27.4 | 23.7 |
|
BSE Sensex
| -11.7 | -4.8 | 1.1 | -8.2 | 3.9 | 5.1 | 10.0 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Harrow Health (HROW)
| 46.1 | 196.9 | -24.1 | 70.8 | 25.9 | -11.8 | 36.7 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Harrow Health (HROW)
|
34.5 | 1,444.8 | 275.6 | -37.2 | 0.2 | -110.1 | -- | 96.2 |
| 17.0 | 5,924.5 | 3,117.6 | 157.4 | 14.7 | -- | 35.4 | 177.9 | |
| 220.8 | 10,826.1 | 776.6 | -191.6 | -17.6 | -223.4 | -- | 131.0 | |
| 72.4 | 14,630.7 | 691.8 | -696.2 | -89.1 | -- | -- | 123.7 | |
| 112.8 | 12,065.9 | 830.8 | 54.9 | 3.2 | 8.1 | 248 | 17.3 | |
| 11.9 | 9,754.3 | 332,834.2 | 33,166.6 | 11.1 | 8.9 | 28.6 | 2.4 | |
| 23.2 | 11,421.4 | 5,020.0 | -199.0 | 1.6 | -3 | -- | 1.8 | |
| 284.5 | 5,693.6 | 290.5 | 197.2 | 82.5 | 19.9 | 29.8 | 5.9 | |
| 66.7 | 6,145.7 | 450.9 | 138.6 | 39.1 | 115.6 | 49 | 30.7 | |
| 127.2 | 8,210.6 | 431.8 | -136.7 | -30.8 | -30.3 | -- | 19.0 |
Shareholding Pattern
View DetailsAbout Harrow Health (HROW)
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers... ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE, as well as BYQLOVI; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; BYOOVIZ, a LUCENTIS biosimilar indicated for the treatment of patients with Neovascular (Wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV); VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; OPUVIZ, an EYLEA biosimilar indicated for the treatment of patients with Wet AMD, macular edema following RVO, diabetic macular edema (DME), and diabetic retinopathy (DR); MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis. In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee. Read more
-
CEO & Chairman of the Board
Mr. Mark L. Baum J.D.
-
CEO & Chairman of the Board
Mr. Mark L. Baum J.D.
-
Headquarters
Nashville, TN
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Harrow Health (HROW)
What is the current share price of Harrow Health Inc (HROW) Today?
The share price of Harrow Health Inc (HROW) is $34.48 (NASDAQ) as of 11-Sep-2026 16:24 EDT. Harrow Health Inc (HROW) has given a return of 32.45% in the last 3 years.
What is the current PB & PE ratio of Harrow Health Inc (HROW)?
Since, TTM earnings of Harrow Health Inc (HROW) is negative, P/E ratio is not available.
The P/B ratio of Harrow Health Inc (HROW) is 96.21 times as on 04-Sep-2026, a 1151 premium to its peers’ median range of 7.69 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-350.51 |
34.35 |
2024 |
-68.72 |
17.25 |
2023 |
-16.22 |
5.63 |
2022 |
-30.83 |
16.16 |
2021 |
-13.18 |
21.03 |
What is the 52 Week High and Low of Harrow Health Inc (HROW)?
The 52-week high and low of Harrow Health Inc (HROW) are Rs 54.85 and Rs 28.54 as of 12-Sep-2026.
What is the market cap of Harrow Health Inc (HROW)?
Harrow Health Inc (HROW) has a market capitalisation of $ 1,445 Mln as on 04-Sep-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Harrow Health Inc (HROW)?
Before investing in Harrow Health Inc (HROW), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.